QH104 (allogeneic B7-H3 CAR γδT) for malignant brain glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

B7‑H3 is highly expressed on many high‑grade glioma cells and tumor-associated endothelial cells, making it an attractive immunotherapy target. QH104 uses allogeneic γδ T cells engineered with a CAR targeting B7‑H3; γδ T cells can recognize tumor cells without MHC restriction and have lower risk of graft‑versus‑host disease. The study is an open‑label, single‑arm dose‑escalation followed by dose‑expansion trial to characterize safety and early signs of anti‑tumor activity. Eligible adults must have B7‑H3–positive, histologically confirmed WHO grade 3–4 glioma with measurable disease and adequate performance status and organ function, and all treatment and follow‑up occur at the sponsoring site in Suzhou, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1)Age 18-70 years old (both ends included), both male and female;
* 2)At least one evaluable lesion, with previous biopsy or histopathological confirmation of high-grade glioma (WHO grade 3-4), and after comprehensive treatment, imaging examination indicates continued progression or recurrence;
* 3\) The pathological tissues removed by surgery can be used for immunohistochemical detection of target proteins (paraffin sections should be within half a year), and the expression of B7-H3 is positive;
* 4\) KPS ≥ 60 points;
* 5)Expected survival \> 3 months;
* 6)Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before receiving QH104 Cell Injection for the first time):White blood cell count (WBC) ≥ 3 x 10\^9/L;Lymphocyte count (LY) ≥ 0.8 x 10\^9/L;Hemoglobin (Hb) ≥ 90g/L;Platelet (PLT) ≥80×10\^9/L;Albumin transaminase (ALT) \& albumin transaminase (AST) \<1.5×ULN;Serum creatinine (Cr) \<1.5 x ULN;Total bilirubin \< 1.5 x ULN;PT \& PTT ≤ 1.25 x ULN.
* 7)No obvious hereditary diseases;
* 8)Normal cardiac function with cardiac ejection index \>55%;
* 9)No bleeding and coagulation disorders;
* 10)Women of childbearing age (15-49 years old) must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception during the clinical trial and for 3 months after the last cell infusion;
* 11\) Sign the informed consent form.

Exclusion Criteria:

* 1)Pregnant and lactating women;
* 2)Those with organ failure:Heart: Class III and IV;Liver: up to grade C of the Child-Turcotte Liver -Function Classification;Kidney: chronic kidney disease stage 4 or above; renal insufficiency stage III or above;Lungs: symptoms of severe respiratory failure with involvement of other organs;Brain: central nervous system abnormalities or impaired consciousness;
* 3)patients with combined second tumors;
* 4)patients with active hepatitis B or C virus, HIV infection, or other untreated active infection;
* 5)any severe, uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis;
* 6)Current systemic use of steroid cell (except for recent or current use of inhaled steroids) substances;
* 7\) have a chronic disease requiring immunologic or hormonal therapy;
* 8\) have an allergy to immunotherapy and related cells;
* 9\) 10)Patients with a history of organ transplantation or who are awaiting organ transplantation;
* 10)Participation in other clinical trials within the previous 30 days;
* 11)Those who are not suitable for clinical trials for other reasons in the opinion of the investigator.

Where it's running

• Dushu Lake Hospital Affiliated to Soochow University
  Suzhou, Jiangsu, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

• Preoperative Proton Therapy for High-Grade Brain Tumors

  This trial tests whether giving proton therapy before surgery is tolerable for people with high-grade brain gliomas.

  Recruiting Phase 1 National Medical Research Radiological Centre of the Ministry of Health of Russia · Obninsk, Kaluga Oblast · NCT07710040

• Neuro-navigation-guided focused ultrasound with nivolumab for relapsed or progressive high-grade brain tumors in children

  This study tests whether using focused ultrasound to open the blood-brain barrier and give nivolumab is safe and feasible for kids with relapsed or progressive DMG/DIPG or other high-grade brain tumors.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia · NCT07664176

• G207 with 5 Gy Radiation for pediatric high-grade glioma

  This study tests whether injecting G207 into a brain tumor plus a single 5 Gy radiation dose is safe and could help extend survival for children with recurrent or progressive high-grade gliomas.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07649070

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Pre-radiation chemotherapy for high-grade glioma

  Researchers are testing whether giving temozolomide before radiation can help patients with newly diagnosed high-grade gliomas see better outcomes and clearer MRI results after treatment.

  Recruiting Phase 2 Cooper Norcross Health · Camden, New Jersey · NCT07439172

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.